Skip to main content

Year: 2025

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…”. The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 medications, including, when medically appropriate, Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk. These programs allow Mangoceuticals patients to access, for the first time, Eli Lilly and Novo Nordisk medications using the Company’s platform. Patients receiving such prescriptions may fill them at any licensed pharmacy of their choice....

Continue reading

Condor Announces 2025 Third Quarter Results

CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based, internationally focused energy transition company focused on Central Asia is pleased to announce the release of its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025 (the “Financial Statements”), together with the related management’s discussion and analysis. These documents will be made available under Condor’s profile on SEDAR+ at www.sedarplus.ca and on the Condor website at www.condorenergies.ca. Readers are invited to review the latest corporate presentation available on the Condor website. All financial amounts in this news release are presented in Canadian dollars, unless otherwise stated. HIGHLIGHTSProduction in Uzbekistan for...

Continue reading

Faraday Future Reports Financial Results for Q3 2025

FX Super One has entered the pre-production phase at its Hanford manufacturing factory with the target of the first FX Super One pre-production vehicle rolling off the line in the U.S. in the near future. Future FF and FX BEV vehicles equipped with NACS charge ports in North America, Japan and South Korea will gain access to 28,000+ Tesla Superchargers, providing more infrastructure convenience for future drivers. FX has now established FX Pars, for FX pre-order holders, in California, New York, Massachusetts, Texas, and Nevada. The next phase of expansion will target New Jersey, Florida, and Washington, where there are strong signs of demand. FF expects to complete a series of safety assessment tests at MGA to ensure full compliance. Secured $136 million in financing commitments. Cash on the balance sheet at quarter-end was at the highest...

Continue reading

Viasat Successfully Tests HaloNet Launch Telemetry Solution for NASA Onboard Blue Origin’s New Glenn

The mission with Blue Origin marks Viasat’s first NASA Communications Services Project (CSP) demonstrationBlue Origin NG-2 on Launch PadViasat’s HaloNet launch telemetry data relay solution was demonstrated for NASA’s Communications Services Project onboard Blue Origin’s New Glenn launch vehicle as part of the NG-2 mission. Photo Credit: Blue OriginCARLSBAD, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Viasat Inc. (NASDAQ: VSAT), a global leader in satellite communications (SATCOM), today announced it successfully executed the first flight test of its launch telemetry data relay service onboard Blue Origin’s New Glenn rocket, which launched from Cape Canaveral earlier today at 3:55pm ET for the second New Glenn mission (NG-2). The demonstration was conducted as part of Viasat’s work under NASA’s Communications...

Continue reading

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. In August 2024, LEQEMBI was approved for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* heterozygotes or non-carriers in the United Kingdom. With this latest approval for IV maintenance...

Continue reading

Cabot Corporation Board Declares Dividend

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) — On Thursday, November 13, 2025, the Board of Directors of Cabot Corporation (NYSE: CBT) declared a quarterly dividend of $0.45 per share on all outstanding shares of the Corporation’s common stock. The dividend is payable on December 12, 2025, to stockholders of record at the close of business on November 28, 2025. About Cabot CorporationCabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company is a leading provider of reinforcing carbons, specialty carbons, battery materials, engineered elastomer composites, inkjet colorants, masterbatches and conductive compounds, fumed metal oxides and aerogel. For more information on Cabot, please visit the company’s website at cabotcorp.com. Safe Harbor Statement...

Continue reading

Madison Pacific Properties Inc. announces the results for the nine months ended September 30, 2025

VANCOUVER, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Madison Pacific Properties Inc. (the Company) (TSX: MPC and MPC.C), a Vancouver-based real estate company announces the results of operations for the nine months ended September 30, 2025. In July 2024, the Company’s Board of Directors approved a change of financial year-end of the Company from August 31 to December 31. This change of year-end is effective for the financial year commencing September 1, 2024. The comparative figures presented for the nine months ended September 30, 2025 are the nine months ended August 31, 2024. The results reported are pursuant to International Financial Reporting Standards (IFRS) for public companies. For the nine months ended September 30, 2025, the Company is reporting a net income of $20.9 million (nine months ended August 31, 2024:...

Continue reading

CORRECTION – POET Technologies Reports Third Quarter 2025 Financial Results

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — In a press release under the same headline issued earlier today by POET Technologies Inc. (TSX Venture: PTK; NASDAQ: POET), please note the second paragraph under “Non-IFRS Financial Summary” should read “a net loss of $17.3 million” rather than “a net income of $17.3 million” as originally issued. Complete corrected text follows.  POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of Photonic Integrated Circuits (PICs), light sources and optical modules for the AI and data center markets, today reported its unaudited condensed consolidated financial results for the third quarter ended September 30, 2025. The Company’s financial results as well as the Management Discussion and Analysis have been...

Continue reading

Binah Capital Group Reports Results for Third Quarter and First Nine Months of 2025

– Grew Total Revenue 10% Year-over-Year to $137.0 Million – – Assets Under Management (“AuM”) Increased 11% Year-over-Year to $30.0 Billion – – Net Income of $2.1 Million – – Increased EBITDA[*] to $5.8 Million from $1.0 Million in the Prior Year – NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter ended September 30, 2025. “In the third quarter this year, we again generated strong results, which reflects the appeal and performance of our differentiated RIA platform,” stated Craig Gould, Chief Executive Officer of...

Continue reading

South Bow Reports Third-quarter 2025 Results, Provides 2026 Outlook, and Declares Dividend

CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — South Bow Corp. (TSX & NYSE: SOBO) (South Bow or the Company) reports its third-quarter 2025 financial and operational results and provides its 2026 outlook. Unless otherwise noted, all financial figures in this news release are in U.S. dollars. Highlights Safety and operational performanceRecorded average throughput of approximately 584,000 barrels per day (bbl/d) on the Keystone Pipeline in the third quarter of 2025, and approximately 703,000 bbl/d on the U.S. Gulf Coast segment of the Keystone Pipeline System.Throughput on the Keystone Pipeline and the U.S. Gulf Coast segment of the Keystone Pipeline System averaged approximately 580,000 bbl/d and approximately 730,000 bbl/d, respectively, during the first nine months of 2025.Achieved mechanical completion for the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.